Updated: Top 50 StR Portfolio Targets Now Live
- BiopharmIQ
- Jul 4
- 1 min read
Our Top 50 StR portfolio targets have been substantially updated. See new targets at the link below.
It's been a tough year thus far for our portfolios vs. XBI. This is unlike last year and almost every other time period that we back-tested previously. A couple of big movers within our portfolios can make a big difference, so we will see how things go for the rest of the year. Our Top 50 StR portfolio is our only portfolio that is about equal to XBI in performance this year. That portfolio is up ~51% since 9/30/23 vs. XBI up 13.5% in that time period. All of our portfolios have beat XBI by at least 5% since Sept 30, 2023 except for our Top 15 consensus portfolio.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 7/4/25 EJV & AV
Comments